Effects of tachyplesin on the regulation of cell cycle in human hepatocarcinoma SMMC-7721 cells

World Journal of Gastroenterology

Volumn 9, Issue 3, 2003, Pages 454-458

  Li, Qi Fu ^a   Ouyang, Gao Liang ^a   Peng, Xuan Xian ^a   Hong, Shui Gen ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; MESSENGER RNA; MYC PROTEIN; PEPTIDE DERIVATIVE; PROTEIN P16; PROTEIN P21; PROTEIN P53; TACHYPLESIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; MITOSIS INHIBITION; MUTANT; UPREGULATION;

EID: 0037349777     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i3.454     Document Type: Article

References (31)

1. Yoneda K, Yamamoto T, Ueta E, Osaki T. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett 1998; 133: 35-45
2. Lo Coco F, Zelent A, Kimchi A, Carducci M, Gore SD, Waxman S. Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. Cancer Res 2002; 62: 5618-5621
3. Wang Z, Sun G, Shen Z, Chen S, Chen Z. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin Med J 1999; 112: 963-967
4. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: Basic science and clinical applications. Pharmacol Ther 2001; 90: 105-156
5. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000; 21: 1271-1279
6. Gali-Muhtasib H, Bakkar N. Modulating cell cycle: Current applications and prospects for future drug development. Curr Cancer Drug Targets 2002; 2: 309-336
7. Donjerkovic D, Scott DW. Regulation of the G1 phase of the mammalian cell cycle. Cell Res 2000; 10: 1-16
8. Li QF, Ouyang GL, Li CY, Hong SG. Effects of tachyplesin on the morphology and ultrastructure of human gastric carcinoma cell line BGC-823. World J Gastroenterol 2000; 6: 676-680
9. Ouyang GL, Li QF, Peng XX, Liu QR, Hong SG. Effects of tachyplesin on proliferation and differentiation of human hepatocellular carcinoma SMMC-7721 cells. World J Gastroenterol 2002; 8: 1053-1058
10. Nakamura T, Furunaka H, Miyata T, Tokunaga F, Muta T, Iwanaga S, Niwa M, Takao T, Shimonishi Y. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachyplus tridentatus), isolation and chemical structure. J Biol Chem 1988; 263: 16709-16713
11. Spector DL, Goldman RD, Leinwand LA. Cells a Laboratory Manual. Cold Spring Harbor Laboratory Press 1998
12. Steinman RA. Cell cycle regulators and hematopoiesis. Oncogene 2002; 21: 3403-3413
13. Wang J, Barsky LW, Shum CH, Jong A, Weinberg KI, Collins SJ, Triche TJ, Wu L. Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J Biol Chem 2002; 277: 43369-43376
14. Agami R, Bernards R. Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle. Cancer Lett 2002; 177: 111-118
15. WAF1. Oral Oncol 2000; 36: 3-7
16. Gartel AL, Tyner AL. The growth-regulatory role of p21 (WAF1/CIP1). Prog Mol Subcell Biol 1998; 20: 43-71
17. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol 2000;48:190-202
18. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992; 89: 9210-9214
19. Liu MC, Gelmann EP. P53 gene mutations: Case study of a clinical marker for solid tumors. Semin Oncol 2002; 29: 246-257
20. Bartova E, Kozubek S, Kozubek M, Jirsova P, Lukasova E, Skalnikova M, Cafourkova A, Koutna I. Nuclear topography of the c-myc gene in human leukemic cells. Gene 2000; 244: 1-11
21. He Y, Zhang J, Zhang J, Yuan Y. The role of c-myc in regulating mdr-1 gene expression in tumor cell line KB. Chin Med J 2000; 113: 848-851
22. Jiang N, Zhang F, Cao L, Yao K, Li G. c-myc gene inactivation during inducing of nasopharyngeal carcinoma cells with retinoic acid. Chin Med J 2000; 113: 823-826
23. Obaya AJ, Kotenko I, Cole MD, Sedivy JM. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J Biol Chem 2002; 277: 31263-31269
24. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595-5610
25. Chen RC, Su JH, Ouyang GL, Cai KX, Li JQ, Xie XG. Induction of differentiation in human hepatocarcinoma cells by Isoverbascoside. Planta Med 2002; 68: 370-372
26. Yuan SL, Huang RM, Wang XJ, Song Y, Huang GQ. Reversing effect of Tanshinone on malignant phenotypes of human hepatocarcinoma cell line. World J Gastroenterol 1998; 4: 317-319
27. Kiyokama H, Richon VM, Rifkind RA, Marks PA. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol 1994; 14: 7195-7203
28. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999; 274: 22013-22018
29. INK4A in leukemic U-937 cells reveals dissociation between cell cycle and differentiation. Exp Hematol 2001; 39: 1382-1391
30. Hyman T, Rothmann C, Heller A, Malik Z, Salzberg S. Structural characterization of erythroid and megakaryocytic differentiation in Friend erythroleukemia cells. Exp Hematol 2001; 29: 563-571
31. Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, Liu BZ, He YJ. Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res 2001; 25: 793-800